Sponsored by Precision ADVANCE, this Endpoints webinar convened industry leaders to discuss the current state of the industry, and the future of advanced therapies including innovations in research and development, going from treating rare diseases to prevalent conditions, continued investment, and next-generation technologies. The panelists also discussed manufacturing and talent bottlenecks, and innovative reimbursement payment models. This discussion was moderated by Anshul Mangal: President (Precision ADVANCE & Project Farma), and included insights from Dan Kirby: Chief Commercial Officer (Orca Bio), Deborah Phippard: CSO (Precision for Medicine), Devyn Smith: CEO (Arbor Bio), Helen Sabzevari: President & CEO (Precigen) and Chad Salisbury: SVP (Project Farma). 

Key points to be discussed:
  • Current state of the advanced therapy industry
  • Investment landscape for cell and gene therapies in 2024 and beyond
  • New technologies, bottlenecks, and solutions
  • Innovative reimbursement models